Physician profile
Valiant Tan
NPI 1154326718
$3,102.97
in general payments reported to CMS, 2019-2025
21 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $154 · 2021: $263 · 2022: $20.52 · 2023: $315 · 2024: $770 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,180 · Food and Beverage: $1,070 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Food and Beverage | $1,069.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,180.03 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $186.09 | 2019-2024 | Rezlidhia, Tavalisse |
| Stryker Corporation | $154.98 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Array Biopharma INC | $150.00 | 2025 | Mektovi, Braftovi, Lorbrena |
| Stemline Therapeutics INC. | $126.47 | 2021 | |
| Novocure INC. | $125.98 | 2019 | |
| Incyte Corporation | $124.93 | 2021 | |
| Jazz Pharmaceuticals INC. | $124.93 | 2025 | |
| Merck Sharp & Dohme LLC | $123.88 | 2023 | Keytruda |
| Pfizer INC. | $121.86 | 2023 | |
| Genzyme Corporation | $120.28 | 2024 | |
| Eusa Pharma (US) LLC | $116.80 | 2020 | |
| Agios Pharmaceuticals, INC. | $107.08 | 2025 | Pyrukynd |
| Abbvie INC. | $100.87 | 2023-2024 | Venclexta |
| Galvanize Therapeutics, INC | $96.44 | 2025 | Aliya System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $57.94 | 2020-2022 | |
| Lupin INC. | $27.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.40 | 2019 | |
| Amgen INC. | $13.08 | 2019 | |
| Seagen INC. | $12.29 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valiant Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.